A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment

OBJECTIVE: Current type 2 diabetes (T2D) management contraindicates intensive glycemia treatment in patients with high cardiovascular disease (CVD) risk and is partially motivated by evidence of harms in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Heterogeneity in response...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Care
Autors principals: Mariam, Arshiya, Miller-Atkins, Galen, Pantalone, Kevin M., Zimmerman, Robert S., Barnard, John, Kattan, Michael W., Shah, Hetal, McLeod, Howard L., Doria, Alessandro, Wagner, Michael J., Buse, John B., Motsinger-Reif, Alison A., Rotroff, Daniel M.
Format: Artigo
Idioma:Inglês
Publicat: American Diabetes Association 2021
Matèries:
Cardiovascular and Metabolic Risk
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247498/
https://ncbi.nlm.nih.gov/pubmed/33863751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc20-2700
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars